Beställ studier för innohep® (tinzaparin)


Nedan följer en lista över särtryck ur studier som du kan beställa från LEO Pharma.
 

  1. Ange numret och tillhörande titel avseende den studie/de studier du är intresserad av längst ner i kommentarsfältet
  2. Fyll i dina adressuppgifter
  3. Klicka på "Sänd"

Leverans av beställt material sker i samband med besök av läkemedelsrepresentant från LEO Pharma (alternativt via post). Besök av läkemedelsrepresentant förutsätter sjukvårdshuvudmannens godkännande.

Normalt delas ett särtryck per studie ut per besök.

OBS! Denna tjänst är avsedd endast för vårdpersonal.

___________________________________________________  

Titel Författare Källa
VTE    
1. TINZAPARIN IN THE TREATMENT OF VENOUS THROMBOEMBOLISM G.F. Pineo et al Drug Evaluation, Reprinted from Expert Opin. on Pharmacotherapy (2003)4(12):2355-2362
     
LUNGEMBOLI    
2. A COMPARISON OF LOW-MOLECULAR-WEIGHT HEPARIN WITH UNFRACTIONATED HEPARIN FOR ACUTE PULMONARY EMBOLISM Gérald Simmonneau et al The New England Journal of Medicine 337:663-669, 1997
     
DVT    
3. SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH CONTINUOUS INTRAVENOUS HEPARIN IN THE TREATMENT OF PROXIMAL-VEIN THROMBOSIS Russel D Hull et al The New England Journal of Medicine 326:975-982, 1992
     
4. PREVENTION OF PERIOPERATIVE DEEP VEIN THROMBOSIS IN GENERAL SURGERY: A MULTICENTRE DOUBLE BLIND STUDIE COMPARING TWO DOSES OF LOGIPARIN AND STANDARD HEPARIN A. Liezorovicz et al Br.J Surg, 1991 Vol 78, 412 – 416
5. PREVENTION OF DEEP VEIN THROMBOSIS AFTER HIP REPLACEMENT. Comparison between Two Low-molecular-weight Heparins, Tinzaparin and Enoxaparin André Planès et al Thrombosis and Haemostasis Vol 81, No 1, 22-25 1999
6. OUT-PATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS I.Mattiasson et al International Angiology Vol 17 , no 3 sept 1998
     
CANCER    
7. LONG-TERM LOW-MOLECULAR-WEIGHT HEPARIN VERSUS USUAL CARE IN PROXIMAL-VEIN THROMBOSIS PATIENTS WITH CANCER Russel D Hull et al Reprinted from The American Journal of Medicine 2006;119:1062-1072
     
ÄLDRE    
8. ELDERLY PATIENTS TREATED WITH TINZAPARIN (Innohep®) ADMINISTERED ONCE DAILY(175 ANTI Xa iu/kg): anti Xa and anti IIa activities over 10 days V. Siguret et al Thrombosis and Haemostasis. Vol 84, No 5, 800-804, 2000
9. SAFETY PROFILE OF TINZAPARIN ADMINISTERED ONCE DAILY AT A STANDARD CURATIVE DOSE IN TWO E. Pautas et al Drug Safety 2002;25(10):725-733
     
GRAVIDA    
10. TINZAPARIN SODIUM FOR THROMBOSIS TREATMENT AND PREVENTION DURING PREGNANCY M.P. Smith et al Reprinted from American Journal of Obstetrics and Gynecology, February 2004, volume 190, number 2
     
 OBESA    
11. DOSING IN HEAVY-WEIGHT/OBESE PATIENTS WITH THE LMWH, TINZAPARIN: A PHARMACODYNAMIC STUDY J.W. Hainer et al Thromb Haemost 2002;87:817-23
     
LÅNGTIDSBEHANDLING    
12. SELF-MANAGED LONG-TERM LOW-MOLECULAR-WEIGHT HEPARIN THERAPHY: THE BALANCE OF BENEFITS AND HARMS Russel D Hull et al Reprinted from The American Journal of Medicine 2007;120:72-82
     
PROFYLAX    
13. COMPARISON OF THE THROMBOPROPHYLACTIC EFFECT OF A LOW MOLECULAR WEIGHT HEPARIN VERSUS DEXTRAN IN TOTAL HIP REPLACEMENT T.Mätzsch et al Thrombotic and Haemorrhagic Disorders 3/1:25-29, 1991
     
DIALYS    
14. LONGTERM MULTICENTER PROSPECTIVE RANDOMIZED CONTROLLED COMPARISON OF TWO LOW MOLECULAR WEIGHT HEPARINS IN HEMODIALYSIS: Tinzaparin (Innohep®) vs Dalteparin (Fragmin) R.J.R Beijering et al Submitted
15. DOSE TITRATION STUDY OF TINZAPARIN, A LOW MOLECULAR WEIGHT HEPARIN, IN PATIENTS ON CHRONIC HEMODIALYSIS Martin Egfjord et al Artificial Organs 22(8):633-637, 1998
16. LONG-TERM EFFECTS OF LOW MOLECULAR WEIGHT HEPARIN ON LIPID PARAMETERS IN HEMODIALYSIS PATIENTS M.S.Elisaf et al